Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22315428 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL7446481 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL28416333 | 0.96 | FOLH1 (0.49) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL24765399 | 0.88 | FOLH1 (0.54) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL14845338 | 0.85 | SIRT6 (0.42) | FOLH1GSRCPB2RNPEPMMP9 | |
| SCHEMBL20887997 | 0.85 | FOLH1 (0.41) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL22859968 | 0.83 | FOLH1 (0.40) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL10047161 | 0.83 | FOLH1 (0.40) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL13891963 | 0.83 | FOLH1 (0.40) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL25602464 | 0.82 | NOD1 (0.49) | SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | MERSANA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210052576-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-5527881-A | SOLID PHASE SYNTHESIS OF FRAGMENTS 1 AND 2 COMPRISING DODECAPEPTIDE AND DECAPEPTIDE, DEPROTECTION TREATMENT OF RESULTING PEPTIDE-RESIN, CLEAVAGE FROM RESIN | LIPOTEC, S.A. (ES) | 1996-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | FOLH1 282/4885GSR 1176/4885CPB2 3146/4885 |
| US-20210228728-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | DARS1, CD2, FCGR2A | FOLH1 282/4885GSR 1176/4885CPB2 3146/4885 |
| US-20230321048-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | FOLH1 1104/4885GSR 2261/4885CPB2 4714/4885 |
| US-20230172910-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | STING1, CGAS, IFNAR1 | FOLH1 1104/4885GSR 2261/4885CPB2 4714/4885 |
| US-20210052576-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | CYP3A4, CYP3A43, CYP11B2 | FOLH1 1828/4885GSR 3091/4885CPB2 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.